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Abstract
Myostatin is a secreted protein that normally acts to limit skeletal muscle growth. As a result, there is considerable interest in
developing agents capable of blocking myostatin activity, as such agents could have widespread applications for the
treatment of muscle degenerative and wasting conditions. Myostatin normally exists in an inactive state in which the
mature C-terminal portion of the molecule is bound non-covalently to its N-terminal propeptide. We previously showed that
this latent complex can be activated in vitro by cleavage of the propeptide with members of the bone morphogenetic
protein-1/tolloid (BMP-1/TLD) family of metalloproteases. Here, I show that mice engineered to carry a germline point
mutation rendering the propeptide protease-resistant exhibit increases in muscle mass approaching those seen in mice
completely lacking myostatin. Mice homozygous for the point mutation have increased muscling even though their
circulating levels of myostatin protein are dramatically increased, consistent with an inability of myostatin to be activated
from its latent state. Furthermore, I show that a loss-of-function mutation in Tll2, which encodes one member of this
protease family, has a small, but significant, effect on muscle mass, implying that its function is likely redundant with those
of other family members. These findings provide genetic support for the hypothesis that proteolytic cleavage of the
propeptide by BMP-1/TLD proteases plays a critical role in the activation of latent myostatin in vivo and suggest that
targeting the activities of these proteases may be an effective therapeutic strategy for enhancing muscle growth in clinical
settings of muscle loss and degeneration.
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Introduction
Myostatin is a transforming growth factor-ß (TGF-ß) family
member that plays a critical role in regulating skeletal muscle mass
[1]. Genetic studies in mice [2], cattle [3–6], sheep [7], dogs [8],
and humans [9] have shown that myostatin normally acts to limit
muscle mass. Mice engineered to lack myostatin have about a
doubling of skeletal muscle weights throughout the body, which
results from a combination of increased fiber numbers and muscle
fiber hypertrophy [2]. Hence, myostatin appears to play at least
two distinct roles in regulating muscle mass, one to regulate the
number of muscle fibers that are formed during development and
a second to regulate muscle fiber growth. Based on this latter
function, there has been considerable interest in developing agents
capable of inhibiting myostatin activity for both agricultural and
human therapeutic applications. In this respect, several engineered
and endogenous myostatin binding proteins have been demon-
strated to be capable of increasing muscle growth when
administered to normal and/or dystrophic mice [10–14].
Like other TGF-ß family members, myostatin is synthesized as a
precursor protein that is cleaved by furin proteases to generate the
active C-terminal dimer. When produced in Chinese hamster
ovary cells, the C-terminal dimer remains bound to the N-terminal
propeptide, which maintains myostatin in a latent, inactive state
[12,15–16]. Most, if not all, of the myostatin protein that circulates
in the blood also appears to exist in an inactive complex with a
variety of proteins, including the propeptide [17–19]. We showed
previously that the latent form of myostatin can be activated in vitro
by dissociating the complex with either acid or heat treatment
[12,17] or by proteolytic cleavage of the propeptide with members
of the BMP-1/TLD family of metalloproteases [12]. Here, I
present genetic evidence suggesting that proteolytic cleavage of the
propeptide may be the primary mechanism by which latent
myostatin is activated in vivo.
Results
Generation and analysis of mice with a protease-resistant
form of the propeptide
In previous studies, we showed that the purified complex of
myostatin propeptide and C-terminal dimer can be cleaved at
aspartate residue 76 by members of the BMP-1/TLD family of
metalloproteases and that cleavage at this site in the propeptide
results in activation of the latent complex [12]. Furthermore, we
showed that changing this aspartate residue to alanine (D76A)
affected neither the ability of the propeptide to form a complex
PLoS ONE | www.plosone.org 1 February 2008 | Volume 3 | Issue 2 | e1628with myostatin nor the ability of the latent complex to be activated
by heat treatment but completely blocked the ability of the
complex to be cleaved and activated by members of the BMP-1/
TLD family. Finally, we showed that unlike the wild type
propeptide, a form of the propeptide containing the D76A amino
acid change could cause significant muscle growth when
administered to mice.
To determine whether this mechanism for activating latent
myostatin functions in vivo, I generated mice in which the aspartate
to alanine change in the propeptide was introduced into the
germline. As shown in Figure 1a, the D76A point mutation was
engineered into a myostatin genomic construct, which was used
for homologous targeting in embryonic stem cells. Following
injection of the targeted embryonic stem cells into blastocysts, I
obtained mice that transmitted the mutant allele through the
germline. These mice were then crossed to EIIa-cre transgenic
mice [20] to remove the neo cassette that had been placed into the
first intron. In order to rule out the possibility that any observed
effects might result from the LoxP site remaining following
removal of the neo cassette, I also generated mice carrying this
LoxP site but which were wild type at aspartate 76. Both of these
lines were backcrossed at least 6 times to C57 BL/6 mice prior to
analysis, and all analysis was carried out on both female and male
mice at 10 weeks of age.
As shown in Table 1 and Figure 2a, mice homozygous for the
LoxP allele but wild type at aspartate 76 had muscle weights that
were comparable to those of wild type mice. In contrast, mice
carrying the D76A point mutation exhibited significant increases
in muscle mass in all four skeletal muscles that were examined as
well as in both males and females. Moreover, the effect of the point
mutation was dose-dependent, with mice heterozygous for the
mutation exhibiting increases of 14–19% and mice homozygous
for the mutation exhibiting increases of 60–99% compared to wild
type mice. This overall pattern was qualitatively similar to that
observed in mice heterozygous or homozygous for a Mstn null
allele; however, the effect of the point mutation was slightly
reduced in magnitude compared to that of the null allele.
In previous studies, we showed that the increases in muscle mass
seen in Mstn null mice result from a combination of increased fiber
numbers and muscle fiber hypertrophy [2]. To determine whether
the same is true for mice carrying the D76A point mutation, I
carried out morphometric analysis of the gastrocnemius/plantaris
muscles. As shown in Table 2 and Figure 2b, total fiber number
was increased by 48% in Mstn
2/2 mice compared to wild type
mice, and mean fiber diameter at the widest point of the muscles
was increased by 16%, which would be predicted to result in an
approximately 34% increase in cross-sectional area. Hence,
consistent with what I reported previously [21], increases in both
fiber number and fiber size appeared to contribute to the increase
in mass seen in the gastrocnemius/plantaris muscles in Mstn
2/2
mice. Similarly, both muscle fiber number and mean fiber
diameter were increased in the gastrocnemius/plantaris muscles
of mice homozygous for the D76A point mutation, although the
effects seen in Mstn
D76A/D76A mice appeared to be slightly lower
than those seen in Mstn
2/2 mice (Table 2 and Figure 2b).
Hence, the phenotype of Mstn
D76A/D76A mice closely resembled
the phenotype of Mstn null mice. Although these findings were
consistent with the point mutation rendering the latent myostatin
complex resistant to activation by BMP-1/TLD proteases, it was
important to rule out the possibility that the point mutation caused
increased muscling by decreasing myostatin expression levels. I first
examined effects of the D76A point mutation on Mstn RNA levels by
Northern analysis. As shown in Figure 1b, analysis of four different
muscles showed that levels of Mstn mRNA were not decreased in
muscles of Mstn
D76A/D76A mice compared to wild type mice and, in
fact, actually appeared to be even slightly increased. Next, I
examined effects of the D76A mutation on circulating myostatin
protein levels. Because I was unable to detect myostatin protein
directly in serum samples by Western analysis using antibodies that
we had prepared against recombinant myostatin protein, I partially
purified the complex of myostatin propeptide and C-terminal dimer
from serum by taking advantage of the ability of both the wild type
and mutant complex to bind hydroxylapatite [12,15]. Western
analysis of the hydroxylapatite-bound material revealed that serum
levels of both the propeptide and the C-terminal domain were
dramatically increased in Mstn
D76A/D76A mice compared to wild type
mice (Figure 1c); in fact, in these experiments, the C-terminal
domain was readily detectable in serum samples from Mstn
D76A/D76A
mice but only barely so in serum samples from wild type mice.
Hence, even though the complex of mutant propeptide and C-
terminaldimerappearstoaccumulatetohighlevelsinMstn
D76A/D76A
mice, the latent complex is unable to be activated, thereby resulting
in increased muscle growth.
Generation and characterization of Tll2 mutant mice
The BMP-1/TLD family consists of four proteins, BMP-1, TLD,
TLL-1, and TLL-2, encoded by three distinct genes (Bmp1, Tll1,a n d
Tll2; for review, see ref. 22). All four of these proteases are capable of
cleaving and activating the latent myostatin complex in vitro [12]. For
two reasons, TLL-2 seemed to be an attractive candidate for the
protease that might be important for regulating myostatin latency.
First, unlike Bmp1 and Tll1, Tll2 is expressed during limb
development specifically in skeletal muscle [23]. Second, although
all four proteases are capable of cleaving the myostatin propeptide,
the range of substrates on which TLL-2 is active appears to be much
more narrow than those of other family members [22], raising the
possibility that regulation of myostatin activity might be one of the
primary functions of TLL-2 in vivo.
To determine whether TLL-2 plays a role in regulating
myostatin latency in vivo, I generated mice carrying a targeted
deletion of the Tll2 gene. The Tll2 gene consists of 21 exons, with
the protease domain being encoded in exons 4–8. As shown in
Figure 3a, I generated a construct in which a LoxP site and a
LoxP/neo cassette were introduced into introns 6 and 7,
respectively. Following homologous recombination in embryonic
stem cells and transfer of the targeted cells into blastocysts, several
chimeric mice were obtained that transmitted the targeted allele
through the germline. Offspring from the chimeric mice were then
mated with EIIa-cre transgenic mice to generate mice in which
exon 7 had been completely deleted. The deletion allele was then
backcrossed six times onto a C57 BL/6 genetic background prior
to analysis. Mice homozygous for the deletion were viable and
fertile, and all analysis was carried out on 10-week old mice.
A deletion of exon 7 is predicted to remove approximately half of
theproteasedomainofTLL-2aswellascauseaframeshiftleadingto
a premature termination codon. Hence, this mutant allele would be
expected to result in a severely truncated product lacking over 85%
ofthe normal protein, including not only halfofthe proteasedomain
but also all of the CUB and EGF domains. The presence of a
premature termination codon near the 59 end of the mRNA also
raised the possibility that the mutant transcript might be subject to
nonsense-mediated decay. To determine whether the mutant
transcript was unstable, I compared RNA levels in brains of wild
type and Tll2
2/2 mice. As shown in Figure 3b, the Tll2 transcript
was readily detected by Northern analysis of poly A-selected brain
RNA prepared from wild type mice. In contrast, the deletion
transcript was undetectable in brains of Tll2
2/2 mice, consistent
with nonsense-mediated decay. Hence, the deletion of exon 7
Activation of Latent Myostatin
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abouthalfoftheproteasedomainbut also ingreatly reduced mRNA
levels and therefore likely results in a severe, if not complete,
reduction in TLL-2 activity.
To determine whether TLL-2 may play a role in regulating
myostatin activity, I measured effects of the Tll2 mutation on
muscle mass. As shown in Table 1 and Figure 3c, mice
homozygous for the Tll2 mutation exhibited slightly increased
Figure 1. Generation of mice carrying a Mstn point mutation rendering the propeptide resistant to cleavage by BMP-1/TLD
proteases. (a) Gene targeting strategy. Black and stippled boxes represent coding exons for the propeptide and C-terminal domain, respectively.
The location of the point mutation (D76A) is denoted by an asterisk, and LoxP sites are denoted by triangles. Removal of the neo cassette using EIIa-
cre mice resulted in Mstn alleles containing a single LoxP site (in intron 1) either with (Mstn
D76A) or without (Mstn
LoxP) the point mutation. (b) Northern
analysis of Mstn RNA expression in mutant mice. Muscle RNA isolated from Mstn
2/2, wild type, and Mstn
D76A/D76A mice was electrophoresed, blotted,
and hybridized with a Mstn probe. The blots were re-hybridized with a probe for the S26 ribosomal protein to control for loading. (c) Analysis of
myostatin protein in mutant mice. Hydroxylapatite-bound serum samples isolated from wild type, Mstn
2/2, and Mstn
D76A/D76A mice were
electrophoresed, blotted, and probed with antiserum directed against either the C-terminal domain [2] or the propeptide [15]. In each gel, the first
lane contains purified myostatin latent complex isolated from Chinese hamster ovary cells [15].
doi:10.1371/journal.pone.0001628.g001
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muscle weights in Tll2
2/2 mice were more pronounced in
females, which exhibited statistically significant increases ranging
from 9–12% depending on the specific muscle. Based on these
results, TLL-2 appears to play at least some role in regulating
muscle growth; however, the fact that the muscle mass increases
seen in Tll2
2/2 mice were significantly lower than those seen in
Mstn
D76A/D76A mice implies that TLL-2 cannot be the sole protease
involved in regulating myostatin latency in vivo.
Discussion
Here, I have presented the results of genetic studies investigating
the mechanisms by which myostatin activity is regulated in vivo.
Previous studies have demonstrated that following processing of
the myostatin precursor protein by furin proteases, the propeptide
remains non-covalently bound to the mature C-terminal dimer
and maintains it in a latent, inactive state [12,15,16]. This latent
complex of the propeptide and C-terminal dimer also appears to
represent the predominant form of myostatin that circulates in the
blood [17,18]. A major question regarding the mechanisms by
which myostatin regulates muscle growth in vivo is how myostatin is
activated from this latent state. In an earlier study, we
demonstrated that members of the BMP-1/TLD family of
metalloproteases are capable of cleaving the myostatin propeptide
and thereby activating the latent myostatin complex in vitro [12]. In
order to determine whether this activation mechanism operates in
vivo, I analyzed the effect of blocking this pathway in mice.
We showed previously that members of the BMP-1/TLD family
can cleave the myostatin propeptide immediately N-terminal to
aspartate residue 76. Furthermore, we showed that changing this
aspartate to alanine (D76A) had no effect on the ability of the
propeptide to form a latent complex with the mature myostatin C-
terminal dimer but rendered the propeptide completely resistant to
proteolysis by BMP-1/TLD proteases in vitro [12]. Here, I have
analyzed the effect of introducing this D76A point mutation into
the endogenous Mstn gene by homologous targeting in mice. I
have presented data showing that mice homozygous for this D76A
mutation exhibit significant increases in muscle mass and, as in the
case of mice completely lacking myostatin, that the increases in
Mstn
D76A/D76A mice result from a combination of increased fiber
numbers and increased fiber sizes. Remarkably, these mice exhibit
significant increases in muscle mass despite the fact that the
circulating levels of myostatin protein in these mice are
dramatically increased compared to wild type mice. Hence, in
Mstn
D76A/D76A mice, myostatin appears to exist in a latent state
that, for the most part, cannot be activated, and as a result, this
latent complex accumulates to high levels. Based on the enhanced
muscling seen in these mutant mice, it seems clear that proteolysis
of the propeptide is the major mechanism by which latent
myostatin is activated in vivo; however, the fact that the increases in
muscle mass seen in these mice are slightly lower than those seen
in mice completely lacking myostatin implies that this cannot be
the sole mechanism for activating the latent complex.
The BMP-1/TLD family consists of four proteins, each of
which is capable of cleaving and activating the latent myostatin
complex in vitro [12]. Based on its expression pattern and substrate
specificity, one of these family members, TLL-2, appeared to be an
attractive candidate for the protease that might be responsible for
activating latent myostatin in vivo. To investigate this possibility, I
generated and analyzed mice carrying a targeted mutation in the
Tll2 gene. Mice homozygous for the Tll2 mutation exhibit
increases in muscle mass, but these increases are relatively small
compared to those seen in either Mstn
–/– or Mstn
D76A/D76A mice.
These results suggest either that TLL-2 plays a relatively minor
role in activating latent myostatin in vivo or that its function is
redundant with those of other members of this protease family.
Clearly, the next step will be to examine the potential roles of
the other members of the BMP-1/TLD family in regulating
myostatin latency. In this regard, it will be important to investigate
the roles of both BMP-1/TLD and TLL-1, as Bmp1 has been
shown to be expressed in skeletal muscle during development in an
overlapping pattern with Tll2, and both Bmp1 and Tll1 have been
shown to be expressed in adult skeletal muscle [23–25]. Given that
genetic studies have shown that complete loss of either BMP-1/
TLD or TLL-1 causes perinatal or embryonic lethality in mice
[26,27], analysis of the roles of these proteases in regulating muscle
Table 1. Muscle weights (mg) of Mstn and Tll2 mutant mice.
offspring sex n pectoralis triceps quadriceps gastrocnemius
Mstn
+/+ Female 11 51.561.6 74.561.2 144.863.7 101.662.3
Mstn
LoxP/LoxP Female 10 54.761.9 77.561.4 150.163.9 104.662.6
Mstn
+/D76A Female 12 61.061.1
a 86.662.0
a 169.363.3
a 116.261.8
a
Mstn
D76A/D76A Female 10 92.764.3
a 134.464.5
a 238.169.3
a 162.365.7
a
Mstn
+/2 Female 12 60.861.3
b 82.561.8
b 172.164.0
a 116.563.2
b
Mstn
2/2 Female 10 106.964.0
a,c 146.664.7
a 271.969.6
a,c 183.464.7
a,d
Tll2
2/2 Female 12 56.061.2
e 81.861.9
f 162.862.6
b 112.362.0
f
Mstn
+/+ Male 11 78.563.7 101.363.2 196.767.7 137.964.4
Mstn
LoxP/LoxP Male 12 78.861.7 98.262.7 189.465.1 134.063.5
Mstn
+/D76A Male 15 93.562.5
f 120.963.0
b 226.266.9
f 157.963.9
f
Mstn
D76A/D76A Male 10 156.268.8
a 201.2610.2
a 335.9614.9
a 234.568.9
a
Mstn
+/2 Male 12 95.262.8
f 119.463.7
b 238.166.8
b 163.864.0
b
Mstn
2/2 Male 10 212.463.6
a,g 229.165.6
a,c 417.869.4
a,h 287.564.9
a,g
Tll2
2/2 Male 15 83.161.1 106.161.6 213.162.9 149.161.1
e
ap,0.0001 vs. wild type;
bp,0.001 vs. wild type;
cp,0.05 vs. Mstn
D76A/D76A;
dp,0.01 vs. Mstn
D76A/D76A;
ep,0.05 vs. wild type;
fp,0.01 vs. wild type;
gp,0.0001 vs.
Mstn
D76A/D76A;
hp,0.001 vs. Mstn
D76A/D76A
doi:10.1371/journal.pone.0001628.t001
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proteases can be eliminated in a tissue-specific manner.
The elucidation of the precise roles played by each of these
proteases will be essential for targeting this regulatory mechanismfor
the development of drugs capable of blocking myostatin activity.
These studies are particularly important in that the relevant protease
or proteases would represent an attractive target for small molecule
drug screening. Although several biologics have been identified that
can target myostatin activity and promote muscle growth, the
development ofsmallmoleculeinhibitorscapableofmimicking these
effects has been hampered by the general paucity of suitable targets
for drug screening. The studies presented here should provide a
strong impetus for further pursuing these proteases for the
development of agents capable of promoting muscle growth in
clinical settings where increasing muscle strength may be beneficial.
Methods
Targeting constructs were generated from phage clones isolated
from a 129 SvJ genomic library [2]. R1 embryonic stem cells were
kindly provided by A. Nagy, R. Nagy, and W. Abramow-Newerly.
Blastocyst injections of targeted clones were carried out by the
Johns Hopkins Transgenic Core Facility. All mice, including
Mstn
2/2 mice [2], were backcrossed at least 6 times onto a C57
Figure 2. Analysis of muscles of mutant mice. (a) Muscle weight increases in Mstn
D76A/D76A mice. Numbers represent percent increases relative
to wild type mice and were calculated from the data shown in Table 1. Muscles analyzed were: pectoralis (red), triceps (gray), quadriceps (blue), and
gastrocnemius (green). (b) Distribution of fiber diameters. Gray bars represent muscle fibers from wild type mice, and red bars represent muscle fibers
from Mstn
2/2 and Mstn
D76A/D76A.
doi:10.1371/journal.pone.0001628.g002
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genotype n total fiber number
relative fiber
number
mean fiber
diameter (mm)
relative fiber
diameter
relative cross-
sectional area
a
Mstn
+/+ 5 84306225 1.00 42.460.9 1.00 1.00
Mstn
D76A/D76A 5 121236538
b 1.44 47.561.3
c 1.12 1.26
Mstn
2/2 3 1249561138
d 1.48 49.060.8
b 1.16 1.34
acalculated as relative fiber diameter squared,
bp,0.001 vs. Mstn
+/+,
cp,0.01 vs. Mstn
+/+;
dp,0.05 vs. Mstn
+/+
doi:10.1371/journal.pone.0001628.t002
Figure 3. Generation and analysis of mice carrying a loss-of-function mutation in the Tll2 gene. (a) Gene targeting strategy. Locations of
exons 6–9 are shown as black boxes, and LoxP sites are denoted by triangles. (b) Northern analysis of Tll2 expression levels. Twenty micrograms of
poly A-selected brain RNA isolated from either wild type or Tll2
2/2 mice were electrophoresed, blotted, and hybridized with a Tll2 probe
corresponding to exons 1–3. The blot was re-hybridized with a probe for the S26 ribosomal protein to control for loading. (c) Muscle weight increases
in Tll2
2/2 mice. Numbers represent percent increases relative to wild type mice and were calculated from the data shown in Table 1. Muscles
analyzed were: pectoralis (red), triceps (gray), quadriceps (blue), and gastrocnemius (green).
doi:10.1371/journal.pone.0001628.g003
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10-week old mice. All animal experiments were carried out in
accordance with protocols that were approved by the Institutional
Animal Care and Use Committee at Johns Hopkins University
School of Medicine.
For measurement of muscle weights, individual muscles were
dissected from both sides of the animal, and the average weight
was calculated. For morphometric analysis, the gastrocnemius and
plantaris muscles were sectioned to their widest point using a
cryostat, and fiber diameters were measured from hematoxylin
and eosin stained sections. Fiber measurements were carried out
on 250 fibers per animal, and mean fiber diameters were
calculated for each animal. For plotting the distribution of fiber
sizes, all data for a given genotype were pooled.
For analysis of myostatin protein, the myostatin latent complex
was partially purified based on its ability to bind hydroxylapatite
[15]. Mouse serum was diluted five-fold with 50 mM Tris pH 7.4
and bound to hydroxylapatite. After washing the column with
50 mM sodium phosphate pH 7.2, the myostatin latent complex
was eluted with 200 mM sodium phosphate pH 7.2. The eluate
was dialyzed, lyophilized, and subjected to Western analysis.
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